AbbVieXSWX:ABBV 65 Receivables Turnover is 1.19 as of Mar. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF167.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 946 Drug Manufacturers companies, AbbVie ranks worse than 50.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. AbbVie's Revenue for the
three
months ended in Mar. 2026 was CHF11,811 Mil. AbbVie's average Accounts Receivable for the
three
months ended in Mar. 2026 was CHF9,928 Mil.
Hence, AbbVie's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.19.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
AbbVie Receivables Turnover Related Terms
AbbVie Receivables Turnover Historical Data
* Premium members only.
The historical data trend for AbbVie's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABBV vs MRK, JNJ, AMGN: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, AbbVie's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where AbbVie's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (XSWX:ABBV) has a Receivables Turnover of 1.19 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on AbbVie and its competitors. According to the industry distribution chart, AbbVie ranks #482 out of 946 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is AbbVie's Receivables Turnover too high?
AbbVie's current Receivables Turnover is 1.19. The Drug Manufacturers industry median Receivables Turnover is 5.07. AbbVie's value of 1.19 is 76.5% below this industry median. Based on the distribution chart, AbbVie ranks #482 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Receivables Turnover compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #482 out of 946 companies for Receivables Turnover. This places AbbVie in the lower half of its industry. The industry median Receivables Turnover is 5.07. AbbVie's value of 1.19 is 76.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current Receivables Turnover of 1.19 is 76.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current Receivables Turnover is 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF167.66, compared to a current price of CHF206.75 — trading 23.3% above its estimated fair value. The current Receivables Turnover is 1.19 and 76.5% below the Drug Manufacturers industry median of 5.07. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current Receivables Turnover is 1.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (XSWX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for XSWX:ABBV:
Receivables Turnover: 1.19
GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
Industry Position: 76.5% below the Drug Manufacturers median (#482 of 946)
No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score
Get the complete analysis for XSWX:ABBV
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABBV has been successfully added to your 
